MATERNAL TESTING FOR ABO/RH & UNEXPECTED ANTIBODIES
ABO/Rh Serology and Antibody Screening for clinically significant red cell antibodies
(results provided within 24 hours)
Extended testing (if indicated)
Antibody identification, antibody titer DNA sequencing to resolve weak RhD phenotype or ABO discrepancy
Results report provided by secure e-mail or fax
WORKUP FOR HEMOLYTIC DISEASE OF THE NEWBORN (HDN)
ABO, Rh, and Direct Antiglobulin Test (DAT) on cord blood sample
(results provided within 24 hours)
Extended testing (if indicated)
Elution Antibody identification
Results report provided by secure e-mail or fax

References:

  1. A joint statement released by the American Association of Blood Banks (AABB) and the College of American Pathologists (CAP) in July of 2015 recommends RHD genotyping of all pregnant women and other females of childbearing potential with a serologic weak D phenotype: "The immediate benefit of determining the RHD genotype of pregnant women with weak D phenotype will be fewer unnecessary injections of Rh immune globulin." (www.aabb.org/advocacy/statements/Pages/statement150722.aspx)

This information is intended for physicians and healthcare professionals only.

Product registration and availability vary by country. For more information on product availability, please contact us here.